Chordoma Foundation Labs
@CFLabsResearch
Followers
177
Following
631
Media
11
Statuses
133
Patient driven research laboratory 100% dedicated to accelerating cures for chordoma. A program of @ChordomaFDN.
Durham, NC
Joined March 2024
Pretty amazing summary of TBXT from @grok
https://t.co/sXoqA5ZJ1z Even references the TBXT Challenge!
grokipedia.com
The T-box transcription factor T, encoded by the TBXT gene and commonly known as Brachyury, is an embryonic nuclear transcription factor essential for vertebrate development, particularly in the...
2
0
1
P53 mutations are very rare in chordoma but interestingly this new preprint from our grantee Mateusz Bujko and colleagues at @MSCNRIO reports that they are a hallmark of the dedifferentiated subtype. Could have important treatment implications.
researchsquare.com
Introduction: Dedifferentiated (DC) and poorly differentiated chordomas (PDC) are rare, aggressive chordomas with a significantly worse prognosis than conventional chordomas (CC). The molecular...
0
0
1
Our grantees at @MDAndersonNews have uncovered a way to direct the immune system against brachyury, and their discoveries led to NIH funding for a clinical trial set to open next year led by @APConley77. Plus, we and @CancerResearch just co-awarded a new grant to the MD Anderson
0
6
16
Congrats to @CatyLeechang, JP Wolinsky, and the @NorthwesternMed team on this publication, which will help set the stage for future chordoma immunotherapy success. And many thanks to @CancerResearch and our supporters for making this important work possible! Paper here:
academic.oup.com
AbstractBackground. Chordomas are locally aggressive notochordal tumors with no systemic therapy options. As an ultra-rare cancer type, our understanding o
Important new paper reveals critical features of the chordoma immune landscape and lays the foundation for chordoma patients to benefit from immunotherapy advances. In brief, it: - Provides the largest spatial data set to date including single cell RNA-seq, TCR profiling and
0
2
6
Important new paper reveals critical features of the chordoma immune landscape and lays the foundation for chordoma patients to benefit from immunotherapy advances. In brief, it: - Provides the largest spatial data set to date including single cell RNA-seq, TCR profiling and
1
1
3
TBXT is present in many cancers, especially chordoma, but barely expressed in normal tissue. Aiming to exploit this difference, Cassian Yee and colleagues at @MDAndersonNews have found that TBXT peptides are expressed on MHC receptors and are now developing cell therapies to
grateful to our group involved w/our new #sarcoma SPORE grant. Under @GorlickRichard & Andy Futreal, we have 2 projects (#chordoma & #osteosarcoma). This involves multiple departments. public link: https://t.co/pt1psG6K9Q. Science: Cassian Yee, Shulin Li, Gorlick, & Futreal
2
2
6
This from @sajithw pinpoints a big source of drag in research and drug development: “Each lab reinvents how experiments are designed, samples are identified, complex data are structured, analysis pipelines run, and results are shared. That’s not even considering work that’s
Long time lurker, breaking a decade of silence to share an essay on what I've learned from scientists about making medicines (spoiler: it's hard) and why the future looks bright (also spoiler: AI) 🧵
1
0
3
New TBXT targeting tools and potential therapeutic targets in the TBXT regulatory network identified by our colleagues Drs. Umbaugh, Scholl @StefanFrohling and team at @DKFZ & @NCT_HD. Exciting work and lots for the field to build on!
science.org
Designed ankyrin repeat proteins targeting the embryonic transcription factor TBXT provide insights into chordoma biology.
0
0
3
We're seeing nice synergy between inhibitors of PKMYT1 and Wee1 in chordoma cells, suggesting a possible combination therapy approach to exploit replication stress in chordoma. Initial results now on @figshare. More to come on this.
figshare.com
To evaluate PKMYT1 inhibition and Wee1 inhibition as a potential combination therapy in chordoma, chordoma cell lines were treated with Lunreseritb and Debio 0123 as single agent treatments and as a...
0
1
2
Latest negative result: Response of chordoma cell lines to treatment with the KIF18A inhibitor sovilnesib (AMG 650), as a single agent and in combination with gemcitabine
figshare.com
To evaluate KIF18A inhibitors as a potential therapeutic target, chordoma cell lines were treated with sovilnesib. A panel of four chordoma cell lines was seeded in a white-walled 96-well plate so...
0
0
1
monitoring the situation as a shipment of precious chordoma samples from our biobank flys to Melbourne for our collaborators in the Firestein lab at @Hudson_Research ✈️ 🇦🇺
0
0
1
Potent GCL inhibitors that induce #ferroptosis (cell death) are ineffective in vitro in chordoma-sensitive cell lines. Highlights the importance of understanding cell-state dependencies in cancer. Negative results are as important as positives.
Positive results get publications and fanfare, but we think sharing negative results is important too. In case this can be helpful to anyone, here are some compounds we tested in vitro in recent months which didn't show substantial activity as single agents or synergy with known
0
1
7
Preclinical chordoma models are insensitive to DNA Polymerase θ inhibition, even when combined with replication stress inducer gemcitabine
figshare.com
To evaluate DNA Polymerase θ as a potential therapeutic target, chordoma cell lines were treated with ART558. A panel of 4 chordoma cell lines were seeded in a white-walled 96-well plate so that at...
1
0
1
Response of chordoma cell lines to the PRMT5 inhibitor AMG 193
figshare.com
To evaluate PRMT5 as a potential therapeutic target in chordoma, MTAP-null (A-C) and MTAP-positive (D-E) chordoma cells were treated with the PRMT5 inhibitor AMG 193 as a single agent, AMG 193 +...
1
0
0
Response of chordoma cell lines to the DNA-PK inhibitor M3814 https://t.co/8AF88KBhOO
figshare.com
To evaluate DNA-PK as a potential therapeutic target, chordoma cells were treated with the DNA-PK inhibitor M3814 as a single agent and in combination with elimusertib, an ATR inhibitorCell lines...
1
0
0
Response of chordoma cell lines to the Aurora A kinase inhibitor Alisertib
figshare.com
To evaluate Aurora A kinase as a potential therapeutic target, chordoma cells were treated with the Aurora A kinase inhibitor alisertib as a single agent and in combination with gemcitabine.Cell...
1
0
1